日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

RTHP-33. A SINGLE INSTITUTION RETROSPECTIVE ANALYSIS ON SURVIVAL BASED ON TREATMENT PARADIGMS FOR PATIENTS WITH ANAPLASTIC OLIGODENDROGLIOMA

RTHP-33. 基于治疗模式的间变性少突胶质瘤患者生存率的单中心回顾性分析

Brouquet, Antoine; Overman, Michael J; Kopetz, Scott; Maru, Dipen M; Loyer, Evelyne M; Andreou, Andreas; Cooper, Amanda; Curley, Steven A; Garrett, Christopher R; Abdalla, Eddie K; Vauthey, Jean-Nicolas; Young, Jacob; Zhang, Yalan; Molinaro, Annette; Taylor, Jennie; Clarke, Jennifer; Prados, Michael; Chang, Susan; Berger, Mitchel; Butowski, Nicholas; Ann Oberheim-Bush, Nancy

Antitumor activity in RAS-driven tumors by blocking AKT and MEK

通过阻断AKT和MEK,在RAS驱动的肿瘤中发挥抗肿瘤活性

Tolcher, Anthony W; Khan, Khurum; Ong, Michael; Banerji, Udai; Papadimitrakopoulou, Vassiliki; Gandara, David R; Patnaik, Amita; Baird, Richard D; Olmos, David; Garrett, Christopher R; Skolnik, Jeffrey M; Rubin, Eric H; Smith, Paul D; Huang, Pearl; Learoyd, Maria; Shannon, Keith A; Morosky, Anne; Tetteh, Ernestina; Jou, Ying-Ming; Papadopoulos, Kyriakos P; Moreno, Victor; Kaiser, Brianne; Yap, Timothy A; Yan, Li; de Bono, Johann S

Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial

直肠癌术前放疗联合卡培他滨、贝伐单抗和厄洛替尼治疗:一项 I 期试验

Das, Prajnan; Eng, Cathy; Rodriguez-Bigas, Miguel A; Chang, George J; Skibber, John M; You, Y Nancy; Maru, Dipen M; Munsell, Mark F; Clemons, Marilyn V; Kopetz, Scott E; Garrett, Christopher R; Shureiqi, Imad; Delclos, Marc E; Krishnan, Sunil; Crane, Christopher H

Rare Though Not Mutually Exclusive: A Report of Three Cases of Concomitant KRAS and BRAF Mutation and a Review of the Literature

罕见但并非互斥:KRAS 和 BRAF 基因同时突变三例报告及文献综述

Sahin, Ibrahim Halil; Kazmi, Syed M A; Yorio, Jeffrey T; Bhadkamkar, Nishin A; Kee, Bryan K; Garrett, Christopher R

Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.

对伊马替尼治疗失败后胃肠道间质瘤患者的舒尼替尼随机、安慰剂对照 III 期试验进行完整的纵向分析

Demetri George D, Garrett Christopher R, Schöffski Patrick, Shah Manisha H, Verweij Jaap, Leyvraz Serge, Hurwitz Herbert I, Pousa Antonio Lopez, Le Cesne Axel, Goldstein David, Paz-Ares Luis, Blay Jean-Yves, McArthur Grant A, Xu Qiang Casey, Huang Xin, Harmon Charles S, Tassell Vanessa, Cohen Darrel P, Casali Paolo G

High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome

晚期结直肠癌肝转移瘤两阶段切除术后生存率高:基于疗效的筛选和完全切除决定预后

Brouquet, Antoine; Abdalla, Eddie K; Kopetz, Scott; Garrett, Christopher R; Overman, Michael J; Eng, Cathy; Andreou, Andreas; Loyer, Evelyne M; Madoff, David C; Curley, Steven A; Vauthey, Jean-Nicolas

Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT

一项针对患有含有活化 AKT 的实体瘤的成年受试者的 I 期药代动力学和药效学研究,评估了 AKT 磷酸化小分子抑制剂——磷酸三西立宾一水合物的疗效。

Garrett, Christopher R; Coppola, Domenico; Wenham, Robert M; Cubitt, Christopher L; Neuger, Anthony M; Frost, Timothy J; Lush, Richard M; Sullivan, Daniel M; Cheng, Jin Q; Sebti, Saïd M

Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin

YM155(一种小分子survivin抑制剂)的I期临床试验和药代动力学研究

Tolcher, Anthony W; Mita, Alain; Lewis, Lionel D; Garrett, Christopher R; Till, Elizabeth; Daud, Adil I; Patnaik, Amita; Papadopoulos, Kyri; Takimoto, Chris; Bartels, Pamela; Keating, Anne; Antonia, Scott

Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab

利用抗表皮生长因子受体抗体靶向治疗结直肠癌:聚焦帕尼单抗

Hoda, Daanish; Simon, George R; Garrett, Christopher R